No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Oramed Pharmaceuticals Welcomes New Audit Committee Chair
Oramed Pharmaceuticals Updates Stock Sale Strategies and Partners
Oramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
Oramed Plans New US Trial for Oral Insulin After Setback, Partners With HTIT to Commercialize Products
Oramed Pharmaceuticals CEO Updates Shareholders on Strategy
MQ, ORMP and EXAI Are Among Pre Market Gainers
No Data